Tom graduated University of Brighton with a BA (Hons) degree in Broadcast Journalism, leaving as the valedictorian of the class of 2015. His final year projects and dissertation were nominated for, and won, several awards, whilst he was also the Editor-in-Chief of the university’s news site during his time at Brighton. After previously writing for a property magazine, Tom joined the Proactive team in January 2016.
The positive data keeps Redx on track to lodge a clinical trial application and investigational new drug application for RXC005 later this year
That’s according to Deutsche Bank, but analysts at HSBC aren’t quite so sure
Merck seems to be ahead in the race to develop the number one lung cancer treatment, but for how long?
It bodes well for the upcoming readout of the MYSTIC trial which is what investors and the markets are really waiting for
The company launched its SlimBiome, CholBiome and CardioBiome technologies at a tradeshow in Geneva last week
“This agreement, which strengthens the company's intellectual property portfolio, puts ProAxsis in a great position to launch further immunoassays and point of care tests”
Chief executive Tim Mitchell will be giving two presentations today and tomorrow at BioTrinity in Hammersmith, London
The non-exclusive agreement will see Italy-based Nutrilinea produce and commercialise products containing OptiBiotix’s LPLDL strain
The Rookie Investors has still got the Fever(tree), but would he have done had he set a stop-loss?
As I venture into the world of equity trading, here’s the background to my story and where I’m at now
UK housebuilders were in favour with the brokers after a survey showed sentiment is strong in the housing industry
Exane BNP Paribas and Bernstein both upped their recommendations for the supermarket chain